Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PET Drugs Without An IND Get Three More Years For Studies Under FDA Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Q&A document from agency says sponsor does not have to use the same manufacturing process as the reference listed drug.

You may also be interested in...



Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation

The latest drug development news and highlights from our FDA Performance Tracker.

PET Drugs May Get Shorter Path To FDA Approval

For positron emission tomography drugs with low levels of use that are needed to diagnose rare conditions, an expanded access IND may be the best regulatory pathway.

FDA Develops Separate Set Of GMP Requirements For PET Drug Makers

FDA will require commercial manufacturers of approved positron emission tomography drugs to meet new GMP requirements by Dec. 12, 2011. This marks the first time that FDA has mandated separate GMPs for a particular type of drug product

Topics

UsernamePublicRestriction

Register

PS073668

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel